DE602004015406D1 - Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen - Google Patents
Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungenInfo
- Publication number
- DE602004015406D1 DE602004015406D1 DE602004015406T DE602004015406T DE602004015406D1 DE 602004015406 D1 DE602004015406 D1 DE 602004015406D1 DE 602004015406 T DE602004015406 T DE 602004015406T DE 602004015406 T DE602004015406 T DE 602004015406T DE 602004015406 D1 DE602004015406 D1 DE 602004015406D1
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- pregnenolone
- medicament
- methoxy
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229960000249 pregnenolone Drugs 0.000 title 1
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- OGNJZVNNKBZFRM-UHFFFAOYSA-N 1-(5-methoxy-1H-indol-3-yl)-2-propanamine Chemical compound COC1=CC=C2NC=C(CC(C)N)C2=C1 OGNJZVNNKBZFRM-UHFFFAOYSA-N 0.000 abstract 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000002118 epoxides Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003132 pregnenolones Chemical class 0.000 abstract 1
- -1 steroid compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0300507A FR2850023B1 (fr) | 2003-01-17 | 2003-01-17 | Medicaments pour le systeme nerveux |
| PCT/FR2004/000086 WO2004067010A1 (fr) | 2003-01-17 | 2004-01-16 | Utilisation de la 3-methoxy-pregnenolone pour la preparation d’un medicament destine a traiter les maladies neurodegeneratives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004015406D1 true DE602004015406D1 (de) | 2008-09-11 |
Family
ID=32605831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004015406T Expired - Lifetime DE602004015406D1 (de) | 2003-01-17 | 2004-01-16 | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8034798B2 (de) |
| EP (1) | EP1583538B1 (de) |
| AT (1) | ATE402710T1 (de) |
| DE (1) | DE602004015406D1 (de) |
| DK (1) | DK1583538T3 (de) |
| ES (1) | ES2311790T3 (de) |
| FR (1) | FR2850023B1 (de) |
| PT (1) | PT1583538E (de) |
| WO (1) | WO2004067010A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| JP5583976B2 (ja) * | 2007-03-07 | 2014-09-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的プロゲステロン受容体モジュレーターとしてのステロイド誘導体 |
| WO2012160006A1 (en) * | 2011-05-20 | 2012-11-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of cb1 receptor. |
| EP4245369A3 (de) * | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroaktive steroide, zusammensetzungen damit und verwendungen davon |
| ES2621528T3 (es) * | 2012-11-28 | 2017-07-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de 3-(4-sustituido)-bencil éter de pregnenolona |
| CN112375115A (zh) | 2013-03-13 | 2021-02-19 | 萨奇治疗股份有限公司 | 神经活性甾类化合物及其使用方法 |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| JP2018519328A (ja) | 2015-07-06 | 2018-07-19 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP3165225A1 (de) | 2015-11-06 | 2017-05-10 | Mapreg | Nicht biologisch umsetzbare c3-substitutierte pregnenolonderivate zur behandlung von drogenmissbrauch |
| EP3436024A1 (de) | 2016-03-01 | 2019-02-06 | Mapreg | Nicht-biokonvertierbare c3-substituierte pregnenolonderivate zur verwendung bei der behandlung von behandlungsresistenten depressionen |
| US9943528B2 (en) | 2016-03-01 | 2018-04-17 | Mapreg | Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression |
| DK3436022T3 (da) | 2016-04-01 | 2022-06-20 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse heraf |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PL3481846T3 (pl) | 2016-07-07 | 2021-12-20 | Sage Therapeutics, Inc. | 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA |
| CN110023323A (zh) | 2016-09-30 | 2019-07-16 | 萨奇治疗股份有限公司 | C7取代的氧固醇及其作为nmda调节剂的方法 |
| AU2017345399B2 (en) | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MX2019004578A (es) | 2016-10-18 | 2019-10-09 | Sage Therapeutics Inc | Oxisteroles y metodos de uso de los mismos. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| EP0840612A1 (de) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate |
| US6245757B1 (en) * | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| FR2806303B1 (fr) * | 2000-03-17 | 2002-09-27 | Inst Nat Sante Rech Med | Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1347763A4 (de) * | 2000-11-06 | 2005-10-12 | Univ Boston | Neuraktive steroidderivate und verfahren zu ihrer verwendung |
| EP1310258A1 (de) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Steroid-Enantiomere zur Erhöhung des Erinnerungsvermögens und der kognitiven Funktion |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US9339508B2 (en) * | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
-
2003
- 2003-01-17 FR FR0300507A patent/FR2850023B1/fr not_active Expired - Lifetime
-
2004
- 2004-01-16 AT AT04702722T patent/ATE402710T1/de active
- 2004-01-16 ES ES04702722T patent/ES2311790T3/es not_active Expired - Lifetime
- 2004-01-16 DK DK04702722T patent/DK1583538T3/da active
- 2004-01-16 WO PCT/FR2004/000086 patent/WO2004067010A1/fr active IP Right Grant
- 2004-01-16 DE DE602004015406T patent/DE602004015406D1/de not_active Expired - Lifetime
- 2004-01-16 PT PT04702722T patent/PT1583538E/pt unknown
- 2004-01-16 EP EP04702722A patent/EP1583538B1/de not_active Expired - Lifetime
- 2004-01-16 US US10/542,495 patent/US8034798B2/en active Active
-
2008
- 2008-09-26 US US12/232,993 patent/US8334278B2/en active Active
-
2015
- 2015-11-24 US US14/950,178 patent/US10561671B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2311790T3 (es) | 2009-02-16 |
| US20060199790A1 (en) | 2006-09-07 |
| US10561671B2 (en) | 2020-02-18 |
| US20090143347A1 (en) | 2009-06-04 |
| US8334278B2 (en) | 2012-12-18 |
| FR2850023A1 (fr) | 2004-07-23 |
| DK1583538T3 (da) | 2008-12-01 |
| FR2850023B1 (fr) | 2007-04-06 |
| US8034798B2 (en) | 2011-10-11 |
| US20160166586A1 (en) | 2016-06-16 |
| WO2004067010A1 (fr) | 2004-08-12 |
| EP1583538B1 (de) | 2008-07-30 |
| PT1583538E (pt) | 2008-10-30 |
| EP1583538A1 (de) | 2005-10-12 |
| ATE402710T1 (de) | 2008-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| ATE268179T1 (de) | Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
| DE60315492D1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
| SE0104340D0 (sv) | New compounds | |
| NO20070576L (no) | Nye hydantionderivater for behandling av obstruktive luftveissykdommer. | |
| GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
| HUP0301749A2 (hu) | Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk | |
| ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
| DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| ATE340579T1 (de) | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |